文献速递前列腺癌

纳入患者合并症的前列腺癌筛查检出者过度诊断个体化风险:估计与沟通

Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
PubMed 文献 · J Urol · 2019-10-09

研究基于既往前列腺癌筛查与临床诊断模型模拟筛查检出病例,判断其在非癌死亡前是否会发生临床诊断,并以合并症调整人群寿命表估算非癌死亡时间。拟合logistic回归模型后按年龄、前列腺特异抗原水平、Gleason评分和合并症类别估计过度诊断概率,并开发在线计算器,由32名临床专家中的20名反馈后修改解释与合并症输入方式。

要点

  • 过度诊断概率随临床病理变量与合并症状态在4%至78%间变化。
  • 70岁、前列腺特异抗原9.4 ng/ml、Gleason 6者忽略合并症时过度诊断概率为34%。
  • 同例伴严重合并症时过度诊断估计值升至51%。

核心结论

  • 过度诊断概率除年龄外还受合并症状态强烈影响,纳入合并症的个体化估计可能有助于患者与医生共同决策个体化治疗选择。

研究设计与样本

  • 使用既往前列腺癌筛查与临床诊断模型模拟筛查检出病例,判断模型化临床诊断是否发生在非癌死亡之前。
  • 非癌死亡时间基于合并症调整的人群寿命表。
  • 对模拟数据拟合logistic回归模型,按年龄、前列腺特异抗原水平、Gleason评分和合并症类别估计过度诊断概率。
  • 开发在线计算器用于沟通过度诊断估计值,并通过调查32名临床专家评估表面效度与易用性。

主要发现

  • 估计的过度诊断概率在临床病理变量与合并症状态间为4%至78%。
  • 忽略合并症时,70岁、前列腺特异抗原9.4 ng/ml、Gleason 6男性的过度诊断估计概率为34%。
  • 伴严重合并症时该估计值升高至51%。
  • 根据32名专家中20名的反馈,修改了在线计算器对过度诊断的解释及合并症输入方式。

关键数值与推荐

  • 过度诊断估计概率范围为4%至78%,对应不同临床病理变量与合并症状态。
  • 70岁、前列腺特异抗原9.4 ng/ml、Gleason 6且忽略合并症者过度诊断估计概率为34%。
  • 同例伴严重合并症时过度诊断估计概率为51%。

临床怎么用

  • 作者认为纳入合并症的个体化过度诊断估计可能有助于患者与医生就个体化治疗选择进行共同决策。
  • 在线计算器用于沟通过度诊断估计值,其解释与合并症输入方式依据20名专家反馈修改。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Shared patient-physician decision making regarding the treatment of prostate cancer detected by prostate specific antigen screening involves a complex calculus weighing cancer risk and patient life expectancy. We sought to quantify these competing risks using the probability that the cancer was over diagnosed, ie would not have been clinically diagnosed (diagnosed without screening) during the remaining lifetime of the patient. MATERIALS AND METHODS: Using an established model of prostate cancer screening and clinical diagnosis we simulated screen detected cases and determined whether a modeled clinical diagnosis would occur before noncancer death. Time of noncancer death was based on comorbidity adjusted population lifetables. Logistic regression models were fitted to the simulated data and used to estimate over diagnosis probabilities given patient age, prostate specific antigen level, Gleason sum and comorbidity category. An online calculator was developed to communicate over diagnosis estimates. Face validity and ease of use were assessed by surveying 32 clinical experts. RESULTS: Estimated probabilities of over diagnosis ranged from 4% to 78% across clinicopathological variables and comorbidity status. When ignoring comorbidity, the estimated probability of over diagnosis in a 70-year-old man with prostate specific antigen 9.4 ng/ml and Gleason 6 was 34%. With severe comorbidities the estimate increased to 51%. Such a personalization may help inform the choice between active surveillance and definitive treatment. Based on responses from 20 of 32 experts we modified the explanation of over diagnosis for the online calculator and the input method for comorbid conditions. CONCLUSIONS: The probability of over diagnosis is strongly influenced by comorbidity status in addition to age. Personalized estimates incorporating comorbidity may contribute to shared decision making between patients and providers regarding personalized treatment selection.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Gulati R, Psutka SP, Etzioni R, et al. Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication. J Urol. 2019. PMID: 31112106. doi:10.1097/JU.0000000000000346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。